The current valuation score of Indaptus Therapeutics Inc is 6.27, ranking 316 out of 385 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.10, which is -73.58% below the recent high of -0.03 and -2136.15% above the recent low of -2.25.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.